DBV TECHNOLOGIE/S (NASDAQ:DBVT) has been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $13.18.
A number of equities analysts have weighed in on the stock. Goldman Sachs Group assumed coverage on shares of DBV TECHNOLOGIE/S in a research report on Monday, June 17th. They set a “buy” rating and a $14.00 target price for the company. Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. ValuEngine upgraded shares of DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, BidaskClub upgraded shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research report on Thursday, August 15th.
Large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC raised its position in DBV TECHNOLOGIE/S by 10.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 13,284 shares of the company’s stock worth $109,000 after buying an additional 1,229 shares during the last quarter. Quantamental Technologies LLC grew its stake in shares of DBV TECHNOLOGIE/S by 63.9% during the 1st quarter. Quantamental Technologies LLC now owns 4,917 shares of the company’s stock valued at $38,000 after acquiring an additional 1,917 shares during the period. FNY Investment Advisers LLC bought a new position in shares of DBV TECHNOLOGIE/S during the 2nd quarter valued at approximately $102,000. LeJeune Puetz Investment Counsel LLC bought a new position in shares of DBV TECHNOLOGIE/S during the 2nd quarter valued at approximately $108,000. Finally, Parametric Portfolio Associates LLC boosted its stake in DBV TECHNOLOGIE/S by 27.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 66,958 shares of the company’s stock worth $550,000 after purchasing an additional 14,454 shares during the period. Institutional investors and hedge funds own 44.99% of the company’s stock.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Recommended Story: Earnings Reports
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.